Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2023.
-
Busy address KBO
33 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Cancer Drug Development Forum from Sint-Lambrechts-Woluwe, company number BE0738523752, closed financial year 2025 with a result of € 9,186 after tax. For that financial year Cancer Drug Development Forum recorded a gross margin of € 299,956 and equity of € 809,743. Compared with financial year 2024, the result moved from € -10,979 to € 9,186. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.
€ 809,743
▲ 1% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 9,186
▲ still € 10,979 loss in 2024
Profit after tax over the fiscal year.
€ 832,140
▼ 15% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
€ 278,996
▼ 2% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 20,765
▲ 10% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 53,858
▼ 26% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 298,477 | € 276,259 | € 299,956 | ▲ 9% |
| Profit after taxes | € 32,922 | € -10,979 | € 9,186 | ▲ € 20,165 |
| Equity | € 811,536 | € 800,557 | € 809,743 | ▲ 1% |
| Total debts | € 537,246 | € 856,236 | € 856,978 | |
| Cash | € 1,034,050 | € 983,345 | € 832,140 | ▼ 15% |
| Retained profit | € 377,720 | € 366,741 | € 375,927 | ▲ 3% |
| Balance sheet total | € 1,348,782 | € 1,656,793 | € 1,666,721 | ▲ 1% |
Key figures of Cancer Drug Development Forum, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Cancer Drug Development Forum?
What happened at Cancer Drug Development Forum in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jacob Verweij stepped down as director. NBB
- Mark Lawler stepped down as director. NBB
- Axel Glasmacher stepped down as director. NBB
- Elizabeth Ruth Plummer stepped down as director. NBB
- Stefan Nicholas Symeonides stepped down as director. NBB
- Rosa Giuliani stepped down as director. NBB
- Christian Kornelius Schneider stepped down as director. NBB
- Fergus Loughlin Sweeney stepped down as director. NBB
In short
From € 32,922 profit in 2023 to € 9,186 profit in 2025.
Paid € 1,185 in corporate taxes since 2023.
Best year ever: 2023, with € 32,922 profit.
Management
Directors
According to the 2025 annual accounts
Rosa Giuliani
Director
since 2023 · until 2026
Christian Kornelius Schneider
Director
since 2023 · until 2026
Fergus Loughlin Sweeney
Director
since 2023 · until 2026
Jacob Verweij
Director
since 2025 · until 2028
Stefan Nicholas Symeonides
Vice-président du Conseil d'Administration
since 2024 · until 2027
Mark Lawler
Chairman of the board
since 2025 · until 2028
Eva Catarina Edfjall
Director
since 2023 · until 2026
Axel Glasmacher
Trésorier
since 2025 · until 2028
Elizabeth Ruth Plummer
Managing director
since 2025 · until 2028
Establishments
Establishment units
Physical locations of this company
Veldkapelgaarde 30
1200 Sint-Lambrechts-Woluwe
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 33 companies are registered at this address.
All companies at this address →Centre de Sante Universitaire de la Faculte de Medecine de l'Universite Catholique de Louvain (Section francophone)
€ 28,963 revenue · 2024
Services de Santé Mentale de l'UCL à Bruxelles
€ 704 revenue · 2024
Belgische Vereniging voor Medische, Informatica - Société belge d'Informatique médicale
Centre universitaire d'information sur les Professions médicales et-ou paramédicales
European Society of Surgical Oncology
€ 1.2 million revenue · 2025
+28 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0738.523.752
- VAT number
- BE 0738.523.752
- Registered office
- Veldkapelgaarde 30, 1200 Sint-Lambrechts-Woluwe
- Names & denominations
- Cancer Drug Development Forum · CDDF
- Enterprise type
- Rechtspersoon
- Legal form
- Non-profit association
- Legal situation
- Normale toestand
- Start date
- 28 November 2019
- Peppol
- Active · Active since 17 Nov 2025
- Activities · NACE
Verenigingen op het vlak van ziektepreventie en gezondheidsbevordering
Uitgeven van tijdschriften
Uitgeverijen van tijdschriften